ulixacaltamide
ulixacaltamide: developed by 1 company · 1 clinical trial tracked.
ulixacaltamide evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could ulixacaltamide → PRAX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Praxis Precision Medicines, Inc. (PRAX) | Phase 3 |
Clinical Trials (1)
Phase 3, Decentralized, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Randomized Withdrawal, and Long-term Safety Study to Evaluate the Efficacy and Safety of Ulixacaltamide (PRAX-944) in Adults With Essential Tremor
Primary endpoint: Parallel Design: Change from Baseline (CFB) to Week 8 (Day 56) on mADL11 score
Frequently asked questions
Who is developing ulixacaltamide?
ulixacaltamide is being developed by Praxis Precision Medicines, Inc..
How many clinical trials involve ulixacaltamide?
BioSniper tracks 1 clinical trial involving ulixacaltamide.